{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:30:45Z","timestamp":1792521045502,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012670","name":"Dysimmune Diseases Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.autrev.2020.102466","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T06:13:46Z","timestamp":1578377626000},"page":"102466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Razzaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102466_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of Rituximab\u2014the World\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2020.102466_bb0010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3389\/fimmu.2018.01189","article-title":"Reversing autoimmunity combination of rituximab and IVIg","volume":"9","author":"Ahmed","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0015","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.autrev.2018.12.002","article-title":"Rituximab therapy for primary central nervous system vasculitis: a 6 patient experience and review of the literature","volume":"18","author":"Salvarani","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0035","first-page":"1","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","author":"Singh","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2020.102466_bb0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.autrev.2019.02.005","article-title":"Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy","volume":"18","author":"Buonavoglia","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0045","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2014.08.020","article-title":"The efficacy of novel B cell biologics as the future of SLE treatment: a review","volume":"13","author":"Kamal","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0050","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","article-title":"The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives","volume":"16","author":"Favalli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","article-title":"Immunosuppressive therapy for autoimmune bullous diseases","volume":"30","author":"Meurer","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.autrev.2020.102466_bb0065","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0070","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/jid.2008.330","article-title":"Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion","volume":"128","author":"Zambruno","year":"2008","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0080","series-title":"Seminars in Oncology","first-page":"2","article-title":"Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002"},{"key":"10.1016\/j.autrev.2020.102466_bb0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-065X.2008.00627.x","article-title":"Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis","volume":"223","author":"Silverman","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0090","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/art.24722","article-title":"Delayed acquisition of somatic hypermutations in repopulated IgD+CD27+ memory B cell receptors after rituximab treatment","volume":"60","author":"Muhammad","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102466_bb0105","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0110","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.autrev.2011.11.007","article-title":"B-cell depleting agents for ANCA vasculitides: a new therapeutic approach","volume":"11","author":"G\u00f3mez-Puerta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102466_bb0115","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2020.102466_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"19","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2020.102466_bb0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2020.102466_bb0135","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0145","series-title":"Blistering diseases: clinical features, pathogenesis, treatment","first-page":"523","article-title":"The treatment of Pemphigus Vulgaris and Pemphigus Foliaceus","author":"Kim","year":"2015"},{"key":"10.1016\/j.autrev.2020.102466_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clindermatol.2009.06.018","article-title":"Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies","volume":"28","author":"Lo","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2020.102466_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2020.102466_bb0170","first-page":"4390","article-title":"Identification and characterization of circulating human transitional B cells identification and characterization of circulating human transitional B cells","volume":"105","author":"Sims","year":"2011","journal-title":"Rev Lit Arts Am"},{"key":"10.1016\/j.autrev.2020.102466_bb0175","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjog\u0308ren\u2019s syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0180","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","article-title":"Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"167","author":"Bohnhorst","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0185","first-page":"R123","article-title":"Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"1","author":"Rehnberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nri1572","article-title":"Regulation of plasma-cell development","volume":"5","author":"Shapiro-Shelef","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1074-7613(03)00267-X","article-title":"Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells","volume":"19","author":"Shapiro-Shelef","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2020.102466_bb0200","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1","article-title":"Plasma cells for a lifetime?","volume":"32","author":"Manz","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.1002836","article-title":"IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection","volume":"186","author":"Racine","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2009.06.003","article-title":"IgM in microbial infections: taken for granted?","volume":"125","author":"Racine","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2020.102466_bb0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0167-5699(98)01252-3","article-title":"High-avidity autoantibodies to cytokines","volume":"19","author":"Bendtzen","year":"1998","journal-title":"Immunol Today"},{"key":"10.1016\/j.autrev.2020.102466_bb0220","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3892\/or.2015.4095","article-title":"Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (review)","volume":"34","author":"D\u00edaz-Zaragoza","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.autrev.2020.102466_bb0225","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.175.7.4180","article-title":"Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells","volume":"175","author":"Lim","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0230","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8472","article-title":"Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity","volume":"105","author":"Shaw","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102466_bb0235","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1073\/pnas.0400347101","article-title":"Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia\/reperfusion injury","volume":"101","author":"Zhang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102466_bb0240","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.93.5.2019","article-title":"Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease","volume":"93","author":"Ray","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102466_bb0245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.nbt.2009.03.016","article-title":"Natural antibodies and cancer","volume":"25","author":"Vollmers","year":"2009","journal-title":"N Biotechnol"},{"key":"10.1016\/j.autrev.2020.102466_bb0250","first-page":"534","article-title":"IgM and its receptors: structural and functional aspects","volume":"76","author":"Klimovich","year":"2011","journal-title":"Biochem"},{"issue":"8","key":"10.1016\/j.autrev.2020.102466_bb0255","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3389\/fimmu.2017.01056","article-title":"Selective IgM deficiency-an underestimated primary immunodeficiency","volume":"5","author":"Gupta","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.1401203","article-title":"Natural IgM is produced by CD5 \u2212 plasma cells that occupy a distinct survival niche in bone marrow","volume":"194","author":"Reynolds","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-004-0187-x","article-title":"Natural serum IgM maintains immunological homeostasis and prevents autoimmunity","volume":"26","author":"Manson","year":"2005","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.autrev.2020.102466_bb0270","first-page":"927","article-title":"The \u201cearly birds\u201d: natural IgM antibodies and immune surveillance","volume":"20","author":"Vollmers","year":"2005","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.autrev.2020.102466_bb0275","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1073\/pnas.97.3.1184","article-title":"Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM","volume":"97","author":"Boes","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102466_bb0280","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.23.021704.115723","article-title":"Maintenance of serum antibody levels","volume":"23","author":"Manz","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0290","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2020.102466_bb0300","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2020.102466_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102466_bb0310","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0315","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102466_bb0320","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2020.102466_bb0325","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0330","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/ar3042","article-title":"Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients","volume":"12","author":"Rodr\u00edguez-Bayona","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102466_bb0335","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/art.39167","article-title":"Internalization of rituximab and the efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus","volume":"67","author":"Reddy","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0340","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.med.48.1.93","article-title":"Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency","volume":"48","author":"Lee","year":"1997","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0345","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De la torre","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102466_bb0350","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2020.102466_bb0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/bs.ai.2016.03.001","article-title":"Factors That Regulate the Generation of Antibody-Secreting Plasma Cells","volume":"131","author":"Yu","year":"2016","journal-title":"Adv Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0360","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0365","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20040973","article-title":"Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression","volume":"200","author":"Kallies","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0370","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0375","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","article-title":"Steady-state generation of mucosal IgA+plasmablasts is not abrogated by B-cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102466_bb0380","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0385","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.exphem.2005.01.005","article-title":"B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells","volume":"33","author":"Avanzini","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.autrev.2020.102466_bb0390","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2020.102466_bb0395","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0400","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2020.102466_bb0405","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102466_bb0410","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102466_bb0415","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.autrev.2020.102466_bb0420","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ajcp\/102.5.580","article-title":"Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia","volume":"102","author":"Hansen","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.autrev.2020.102466_bb0425","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0430","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102466_bb0435","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0440","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2020.102466_bb0445","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1172\/JCI106283","article-title":"Altered immunoglobulin metabolism in systemic lupus erythematosus and heumatoid arthritis","volume":"49","author":"Levy","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102466_bb0450","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0455","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of Fc?RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0460","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of Fc\u03b3RIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2020.102466_bb0465","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1084\/jem.153.3.694","article-title":"Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae","volume":"153","author":"Briles","year":"1981","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0470","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2020.102466_bb0475","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102466_bb0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","article-title":"Risk factors for infection in haematology patients treated with rituximab","volume":"82","author":"Kanbayashi","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2020.102466_bb0485","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"94","author":"Bonilla","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0490","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102466_bb0495","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-3083.2007.01995.x","article-title":"Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate\/anti-TNF therapy","volume":"66","author":"Bokarewa","year":"2007","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0500","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000222682","article-title":"Clinical and immunological features in IgM deficiency","volume":"150","author":"Yel","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0505","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1081-1206(10)60962-3","article-title":"Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature","volume":"97","author":"Goldstein","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/624850","article-title":"Pediatric selective IgM immunodeficiency","volume":"2008","author":"Goldstein","year":"2008","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0515","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12016-013-8375-x","article-title":"Primary selective IgM deficiency: an ignored immunodeficiency","volume":"46","author":"Louis","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0520","first-page":"214","article-title":"Selective immunoglobulin M deficiency in an adult with Streptococcus pneumoniae sepsis and invasive aspergillosis","volume":"18","author":"Hong","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0525","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.188.12.2381","article-title":"A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection","volume":"188","author":"Boes","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2020.102466_bb0530","first-page":"547","article-title":"IgM deficiency: clinical spectrum and immunologic assessment","volume":"62","author":"Guill","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.autrev.2020.102466_bb0535","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(70)90288-6","article-title":"Immunoglobin deficiencies in an atopic population","volume":"296","author":"Kaufman","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102466_bb0540","first-page":"21","article-title":"Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiency","volume":"5","author":"Louis","year":"2016","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2020.102466_bb0545","doi-asserted-by":"crossref","first-page":"R1001","DOI":"10.1186\/ar1776","article-title":"Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"7","author":"Henneken","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102466_bb0550","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.192.2.271","article-title":"B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection","volume":"192","author":"Baumgarth","year":"2000","journal-title":"J Exp Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:17Z","timestamp":1761599897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1568997220300094"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102466","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102466"}}